Gemcitabine in the management of metastatic breast cancer: a systematic review

[1] Citron ML(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination therapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431-1439

[2] Berry DA(2003)Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976-983

[3] Cirrincione C(2005)Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment node positive cancer Breast Cancer Res Treat 88 S16, A27-2313

[4] Hudis C(2005)Adjuvant docetaxel for node-positive breast cancer New Engl J Med 352 2302-908

[5] Winer EP(2005)Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study J Clin Oncol 23 A581-1408

[6] Gradishar WJ(2003)Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study Proc Am Soc Clin Onc 22 7, A25-1806

[7] Henderson IC(2004)Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study J Clin Oncol 22 A621-21

[8] Berry DA(2004)Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival J Clin Oncol 22 A510-S22

[9] Demetri GD(2005)First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study Ann Oncol 16 899-8

[10] Cirrincione C(2005)Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial J Clin Oncol 23 1401-162

[1] Citron ML(2003)Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination therapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 J Clin Oncol 21 1431-1439

[2] Berry DA(2003)Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976-983

[3] Cirrincione C(2005)Five years analysis of the PACS 01 trial: 6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel (D) for the adjuvant treatment node positive cancer Breast Cancer Res Treat 88 S16, A27-2313

[4] Hudis C(2005)Adjuvant docetaxel for node-positive breast cancer New Engl J Med 352 2302-908

[5] Winer EP(2005)Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): results of a European phase III study J Clin Oncol 23 A581-1408

[6] Gradishar WJ(2003)Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study Proc Am Soc Clin Onc 22 7, A25-1806

[7] Henderson IC(2004)Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): quality of life (QoL) and pain palliation results from the global phase III study J Clin Oncol 22 A621-21

[8] Berry DA(2004)Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival J Clin Oncol 22 A510-S22

[9] Demetri GD(2005)First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study Ann Oncol 16 899-8

[10] Cirrincione C(2005)Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group international, multicenter, prospective, randomized phase III trial J Clin Oncol 23 1401-162